So Yeon Kim, MD, on Consolidation Osimertinib vs Durvalumab vs Observation in EGFR-Mutant NSCLC

Posted: Friday, February 28, 2025

So Yeon Kim, MD, of Yale School of Medicine, shares her thoughts on the early findings of the LAURA trial and how consolidation osimertinib compares with durvalumab or observation after chemoradiotherapy for unresectable stage III EGFR-mutant non–small cell lung cancer (NSCLC).

---